Jeil Pharmaceutical Co.,Ltd
271980.KS
Get informed when a big investor buys or sells
+ FollowMarket Cap$147.78B
Close$
$-9144.50
195% downside
Current Fair Value
195% downsideOvervalued by 195% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $147.78 Billion |
|---|---|
| Enterprise Value | $204.65 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1604.77 |
| Beta | 1.53 |
| Outstanding Shares | 14,705,000 |
Return
| Return on Equity | 4.53% |
|---|---|
| Return on Assets | 1.77% |
| Return on Invested Capital | 4.30% |
Valuation & Multiples
| P/E Ratio | 8.27 |
|---|---|
| PEG | -2.32 |
| Price to Sales | 0.26 |
| Price to Book Ratio | 0.56 |
| Enterprise Value to Revenue | 0.38 |
| Enterprise Value to EBIT | 17.12 |
| Enterprise Value to Net Income | 21 |
| Total Debt to Enterprise | 0.56 |
| Debt to Equity | 0.56 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Jeil Pharmaceutical Co.,Ltd
973 employees
CEO: Seok-Jae Sung Primarily active within South Korea, Jeil Pharmaceutical Co.,Ltd dedicates itself to the development and supply of a broad spectrum of pharmaceutical goods. Its product offerings address numerous therapeutic categories, including antibio...